Key result
Molecular modeling of nucleotide analogs identifies structural features that may yield more potent SARS-CoV-2 inhibitors.
Why the study?
There is a need to develop specific treatments for COVID-19 by targeting SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease to identify potent antiviral agents.
Computational modeling identified key structural features of nucleotide analogs that may inhibit SARS-CoV-2 replication, providing candidates for future drug screening.
May identify candidate COVID-19 therapies; leaves open need for validation before clinical consideration.
The rapid spread and public health impact of the novel SARS-CoV-2 variants that cause COVID-19 continue to produce major global impacts and social distress. Several vaccines were developed in record time to prevent and limit the spread of the infection, thus playing a pivotal role in controlling the pandemic. Although the repurposing of available drugs attempts to provide therapies of immediate access against COVID-19, there is still a need for developing specific treatments for this disease. Remdesivir, molnupiravir and Paxlovid remain the only evidence-supported antiviral drugs to treat COVID-19 patients, and only in severe cases. To contribute on the search of potential Covid-19 therapeutic agents, we targeted the viral RNA-dependent RNA polymerase (RdRp) and the exoribonuclease (ExoN) following two strategies. First, we modeled and analyzed nucleoside analogs sofosbuvir, remdesivir, favipiravir, ribavirin, and molnupiravir at three key binding sites on the RdRp-ExoN complex. Second, we curated and virtually screened a database containing 517 nucleotide analogs in the same binding sites. Finally, we characterized key interactions and pharmacophoric features presumably involved in viral replication halting at multiple sites. Our results highlight structural modifications that might lead to more potent SARS-CoV-2 inhibitors against an expansive range of variants and provide a collection of nucleotide analogs useful for screening campaigns.
No takes yet. Share an insight, caveat, or question.
Madariaga‐Mazón et al. (2022) studied COVID-19. Nucleotide analogs was evaluated on Viral RNA-dependent RNA polymerase (RdRp) and exoribonuclease (ExoN) binding interactions. Molecular modeling and virtual screening of nucleotide analogs identified structural modifications and pharmacophoric features that may yield more potent SARS-CoV-2 inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: